Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization

Detection of ROSI rearrangement in non-small cell lung cancer: Current and future perspectives

Rossi G.
Jocolle G.
Conti A.
Tiseo M.
Marino F. Z.
Donati G.
Franco R.
Bono F.
Barbisan F.
Facchinetti F.

January 2017

ROS1 rearrangement characterizes a small subset (1%–2%) of non-small cell lung cancer and is associa...

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

Conde, E. (Esther)
Hernández, S. (Susana)
Martínez-Turrillas, R. (Rebeca)
Angulo, B. (Bárbara)
Castro, J. (Javier) de
Collazo-Lorduy, A. (Ana)
Jiménez, B. (Beatriz)
Muriel, A. (Alfonso)
Mate, J.L. (Jose Luis)
Moran, T. (Teresa)
Aranda, I. (Ignacio)
Massuti, B. (Bartomeu)
Rojo-Todo, F. (Federico)
Domine, M. (Manuel)
Sansano, I. (Irene)
García, F. (Felip)
Felip, E. (Enriqueta)
Mancheño, N. (Nuria)
Juan, O. (Oscar)
Sanz, J. (Julián)
Gonzalez-Larriba, J.L. (José Luis)
Atienza-Cuevas, L. (Lidia)
Arriola-Arellano, E. (Esperanza)
Abdulkader, I. (Ihab)
García-González, J (Jorge)
Camacho, C. (Carmen)
Rodríguez-Abreu, D. (Delvys)
Teixidó, C. (Cristina)
Reguart, N. (Noemi)
González-Piñeiro, A. (Ana)
Lázaro-Quintela, M. (Martín)
Lozano, M.D. (María Dolores)
Gurpide, A. (Alfonso)
Gomez-Roman, J. (Javier)
López-Brea, M. (Marta)
Pijuan, L. (Lara)
Salido, M. (Marta)
Arriola, E. (Edurne)
Company, A. (Amparo)
Insa, A. (Amelia)
Esteban-Rodríguez, I. (Isabel)
Saiz, M. (Mónica)
Azcona, E. (Eider)
Álvarez, R. (Ramiro)
Artal, Á. (Ángel)
Plaza, M.L. (María Luz)
Aguiar, D. (David)
Enguita, A.B. (Ana Belén)
Benito, A. (Amparo)
Paz-Ares, L. (Luis)
Garrido, P. (Pilar)
López-Ríos, F. (Fernando)

January 2019

Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of...

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort.

Mazières, Julien
Zalcman, Gérard
Crinò, Lucio
Biondani, Pamela
Barlesi, Fabrice
Filleron, Thomas
Dingemans, Anne-Marie C
Léna, Hervé
Monnet, Isabelle
Rothschild, Sacha I
Cappuzzo, Federico
Besse, Benjamin
Thiberville, Luc
Rouvière, Damien
Dziadziuszko, Rafal
Smit, Egbert F
Wolf, Jurgen
Spirig, Christian
Pecuchet, Nicolas
Leenders, Frauke
Heuckmann, Johannes M
Diebold, Joachim
Milia, Julie D
Thomas, Roman K
Gautschi, Oliver

March 2015

International audienceApproximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrang...

Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization

Huang, Richard
Smith, Derek
Le, Catherine
Liu, Wen-Wei
Ordinario, Ellen
Manohar, Chitra
Lee, Michael
Rajamani, Jaya
Truong, Huan
Li, Jing
Choi, Cindy
Li, Jingchuan
Pati, Amrita
Bubendorf, Lukas
Buettner, Reinhard
Kerr, Keith
Lopez-Rios, Fernando
Marchetti, Antonio
Marondel, Ivonne
Nicholson, Andrew, G.
Öz, Ayşim Büge
Pauwels, Patrick
Penault-Llorca, Frédérique
Rossi, Giulio
Thunnissen, Erik
Newell, Amy Hanlon
Pate, Greg
Menzl, Ina

June 2020

International audienceThe ability to determine ROS1 status has become mandatory for patients with lu...

Correlation of ROS1 immunohistochemistry with ROS1 fusion status determined by fluorescence in situ hybridization

Huang, Richard S.P.
Smith, Derek
Le, Catherine H.
Liu, Wen Wei
Ordinario, Ellen
Manohar, Chitra
Lee, Michael
Rajamani, Jaya
Truong, Huan
Li, Jing
Choi, Cindy
Li, Jingchuan
Pati, Amrita
Bubendorf, Lukas
Buettner, Reinhard
Kerr, Keith M.
Lopez-Rios, Fernando
Marchetti, Antonio
Marondel, Ivonne
Nicholson, Andrew G.
Oz, Aysjm Büge
Pauwels, Patrick
Penault-Llorca, Frederique
Rossi, Giulio
Thunnissen, Erik
Newell, Amy Hanlon
Pate, Greg
Menzl, Ina

June 2020

Context.-The ability to determine ROS1 status has become mandatory for patients with lung adenocarci...

Testing for ROS1 in non-small cell lung cancer: a review with recommendations

Bubendorf, Lukas
Buettner, Reinhard
Al-Dayel, Fouad
Dietel, Manfred
Elmberger, Goran
Kerr, Keith
Lopez-Rios, Fernando
Marchetti, Antonio
Oz, Buge
Pauwels, Patrick
Penault-Llorca, Frederique
Rossi, Giulio
Ryska, Ales
Thunnissen, Erik

January 2016

Rearrangements of the ROS1 gene occur in 1-2 % of non-small cell lung cancers (NSCLCs). Crizotinib, ...

ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas

Sholl, Lynette Marie
Sun, Heather
Butaney, Mohit
Zhang, Chengsheng
Lee, Charles
Janne, Pasi Antero
Rodig, Scott J.

May 2017

ROS1 gene rearrangements are reported in 1–2% of lung adenocarcinomas (ACA) and are associated with ...

Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients

Hofman, Véronique
Rouquette, Isabelle
Long-Mira, Elodie
Piton, Nicolas
Chamorey, Emmanuel
Heeke, Simon
Vignaud, Jean Michel
Yguel, Clémence
Mazières, Julien
Lepage, Anne-Laure
Bibeau, Frédéric
Begueret, Hugues
Lassalle, Sandra
Lalvée, Salomé
Zahaf, Katia
Benzaquen, Jonathan
Poudenx, Michel
Marquette, Charles-Hugo
Sabourin, Jean-Christophe
Ilie, Marius
Hofman, Paul

July 2019

International audienceINTRODUCTION:The detection of a ROS1 rearrangement in advanced and metastatic ...

Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer

Pavlakis, Nick
Cooper, Caroline
John, Thomas
Kao, Steven
Klebe, Sonja
Lee, Chee Khoon
Leong, Trishe
Millward, Michael
O'Byrne, Ken
Russell, Prudence A.
Solomon, Benjamin
Cooper, Wendy A.
Fox, Stephen

December 2019

Lung cancer is the most commonly diagnosed malignancy and the leading cause of death from cancer glo...

Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.

Yoon Jin Cha
Jae Seok Lee
Hye Ryun Kim
Sun Min Lim
Byoung Chul Cho
Chang Young Lee
Hyo Sup Shim

ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...

Detection of ROS1 Gene Rearrangement in Lung Adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR

Ling Shan (155985)
Fang Lian (697007)
Lei Guo (36221)
Tian Qiu (156003)
Yun Ling (178318)
Jianming Ying (155982)
Dongmei Lin (495417)

March 2015

<div>AimsTo compare fluorescence in situ hybridization (FISH), immunohistochemistry...

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date

Gendarme, Sébastien
Bylicki, Olivier
Chouaid, Christos
Guisier, Florian

January 2022

The ROS-1 gene plays a major role in the oncogenesis of numerous tumors. ROS-1 rearrangement is foun...

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma : the ROSING Study

Conde, E.
Hernández, Susana
Martinez, R.
Angulo, B.
De Castro, J.
Collazo-Lorduy, A.
Jimenez, B.
Muriel, A.
Mate Sanz, Jose Luís
Morán, Teresa
Aranda, I.
Massuti, B.
Rojo, F.
Domine, M.
Sansano, Irene
Garcia, F.
Felip, Enriqueta
Mancheño, N.
Juan, O.
Sanz, Julián
Gonzalez-Larriba, J.L.
Atienza-Cuevas, L.
Arriola-Arellano, E.
Abdulkader, I.
Garcia-Gonzalez, J.
Camacho, C.
Rodriguez-Abreu, D.
Teixido, C.
Reguart, Noemi
Gonzalez-Piñeiro, A.
Lazaro-Quintela, M.
Lozano, M.D.
Gurpide, A.
Gomez-Roman, J.
Lopez-Brea, M.
Pijuan, Lara
Salido, Marta
Arriola, Edurne
Company, A.
Insa, A.
Esteban-Rodriguez, I.
Saiz, M.
Azkona, E.
Alvarez, R.
Artal, A.
Plaza, M.L.
Aguiar, D.
Enguita, A.B.
Benito, A.
Paz-Ares, L.
Garrido, P.
Lopez-Rios, F.
Universitat Autònoma de Barcelona

Altres ajuts: Funding for this study was provided bythe iLUNG Program (B2017/BMD-3884) from the Comu...

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort

Mazieres, Julien
Zalcman, Gerard
Crino, Lucio
Biondani, Pamela
Barlesi, Fabrice
Filleron, Thomas
Dingemans, Anne-Marie C.
Lena, Herve
Monnet, Isabelle
Rothschild, Sacha I.
Cappuzzo, Federico
Besse, Benjamin
Thiberville, Luc
Rouviere, Damien
Dziadziuszko, Rafal
Smit, Egbert F.
Wolf, Jurgen
Spirig, Christian
Pecuchet, Nicolas
Leenders, Frauke
Heuckmann, Johannes M.
Diebold, Joachim
Milia, Julie D.
Thomas, Roman K.
Gautschi, Oliver

March 2015

Purpose Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement. Crizoti...

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements

Yoon Jin Cha
Jae Seok Lee
Hye Ryun Kim
Sun Min Lim
Byoung Chul Cho
Chang Young Lee
Sup Shim

January 2014

ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...

Detection of ROSI rearrangement in non-small cell lung cancer: Current and future perspectives

Rossi G.
Jocolle G.
Conti A.
Tiseo M.
Marino F. Z.
Donati G.
Franco R.
Bono F.
Barbisan F.
Facchinetti F.

January 2017

ROS1 rearrangement characterizes a small subset (1%–2%) of non-small cell lung cancer and is associa...

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

Conde, E. (Esther)
Hernández, S. (Susana)
Martínez-Turrillas, R. (Rebeca)
Angulo, B. (Bárbara)
Castro, J. (Javier) de
Collazo-Lorduy, A. (Ana)
Jiménez, B. (Beatriz)
Muriel, A. (Alfonso)
Mate, J.L. (Jose Luis)
Moran, T. (Teresa)
Aranda, I. (Ignacio)
Massuti, B. (Bartomeu)
Rojo-Todo, F. (Federico)
Domine, M. (Manuel)
Sansano, I. (Irene)
García, F. (Felip)
Felip, E. (Enriqueta)
Mancheño, N. (Nuria)
Juan, O. (Oscar)
Sanz, J. (Julián)
Gonzalez-Larriba, J.L. (José Luis)
Atienza-Cuevas, L. (Lidia)
Arriola-Arellano, E. (Esperanza)
Abdulkader, I. (Ihab)
García-González, J (Jorge)
Camacho, C. (Carmen)
Rodríguez-Abreu, D. (Delvys)
Teixidó, C. (Cristina)
Reguart, N. (Noemi)
González-Piñeiro, A. (Ana)
Lázaro-Quintela, M. (Martín)
Lozano, M.D. (María Dolores)
Gurpide, A. (Alfonso)
Gomez-Roman, J. (Javier)
López-Brea, M. (Marta)
Pijuan, L. (Lara)
Salido, M. (Marta)
Arriola, E. (Edurne)
Company, A. (Amparo)
Insa, A. (Amelia)
Esteban-Rodríguez, I. (Isabel)
Saiz, M. (Mónica)
Azcona, E. (Eider)
Álvarez, R. (Ramiro)
Artal, Á. (Ángel)
Plaza, M.L. (María Luz)
Aguiar, D. (David)
Enguita, A.B. (Ana Belén)
Benito, A. (Amparo)
Paz-Ares, L. (Luis)
Garrido, P. (Pilar)
López-Ríos, F. (Fernando)

January 2019

Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of...

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort.

Mazières, Julien
Zalcman, Gérard
Crinò, Lucio
Biondani, Pamela
Barlesi, Fabrice
Filleron, Thomas
Dingemans, Anne-Marie C
Léna, Hervé
Monnet, Isabelle
Rothschild, Sacha I
Cappuzzo, Federico
Besse, Benjamin
Thiberville, Luc
Rouvière, Damien
Dziadziuszko, Rafal
Smit, Egbert F
Wolf, Jurgen
Spirig, Christian
Pecuchet, Nicolas
Leenders, Frauke
Heuckmann, Johannes M
Diebold, Joachim
Milia, Julie D
Thomas, Roman K
Gautschi, Oliver

March 2015

International audienceApproximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrang...

Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization

Huang, Richard
Smith, Derek
Le, Catherine
Liu, Wen-Wei
Ordinario, Ellen
Manohar, Chitra
Lee, Michael
Rajamani, Jaya
Truong, Huan
Li, Jing
Choi, Cindy
Li, Jingchuan
Pati, Amrita
Bubendorf, Lukas
Buettner, Reinhard
Kerr, Keith
Lopez-Rios, Fernando
Marchetti, Antonio
Marondel, Ivonne
Nicholson, Andrew, G.
Öz, Ayşim Büge
Pauwels, Patrick
Penault-Llorca, Frédérique
Rossi, Giulio
Thunnissen, Erik
Newell, Amy Hanlon
Pate, Greg
Menzl, Ina

June 2020

International audienceThe ability to determine ROS1 status has become mandatory for patients with lu...

Correlation of ROS1 immunohistochemistry with ROS1 fusion status determined by fluorescence in situ hybridization

Huang, Richard S.P.
Smith, Derek
Le, Catherine H.
Liu, Wen Wei
Ordinario, Ellen
Manohar, Chitra
Lee, Michael
Rajamani, Jaya
Truong, Huan
Li, Jing
Choi, Cindy
Li, Jingchuan
Pati, Amrita
Bubendorf, Lukas
Buettner, Reinhard
Kerr, Keith M.
Lopez-Rios, Fernando
Marchetti, Antonio
Marondel, Ivonne
Nicholson, Andrew G.
Oz, Aysjm Büge
Pauwels, Patrick
Penault-Llorca, Frederique
Rossi, Giulio
Thunnissen, Erik
Newell, Amy Hanlon
Pate, Greg
Menzl, Ina

June 2020

Context.-The ability to determine ROS1 status has become mandatory for patients with lung adenocarci...

Testing for ROS1 in non-small cell lung cancer: a review with recommendations

Bubendorf, Lukas
Buettner, Reinhard
Al-Dayel, Fouad
Dietel, Manfred
Elmberger, Goran
Kerr, Keith
Lopez-Rios, Fernando
Marchetti, Antonio
Oz, Buge
Pauwels, Patrick
Penault-Llorca, Frederique
Rossi, Giulio
Ryska, Ales
Thunnissen, Erik

January 2016

Rearrangements of the ROS1 gene occur in 1-2 % of non-small cell lung cancers (NSCLCs). Crizotinib, ...

ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas

Sholl, Lynette Marie
Sun, Heather
Butaney, Mohit
Zhang, Chengsheng
Lee, Charles
Janne, Pasi Antero
Rodig, Scott J.

May 2017

ROS1 gene rearrangements are reported in 1–2% of lung adenocarcinomas (ACA) and are associated with ...

Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients

Hofman, Véronique
Rouquette, Isabelle
Long-Mira, Elodie
Piton, Nicolas
Chamorey, Emmanuel
Heeke, Simon
Vignaud, Jean Michel
Yguel, Clémence
Mazières, Julien
Lepage, Anne-Laure
Bibeau, Frédéric
Begueret, Hugues
Lassalle, Sandra
Lalvée, Salomé
Zahaf, Katia
Benzaquen, Jonathan
Poudenx, Michel
Marquette, Charles-Hugo
Sabourin, Jean-Christophe
Ilie, Marius
Hofman, Paul

July 2019

International audienceINTRODUCTION:The detection of a ROS1 rearrangement in advanced and metastatic ...

Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer

Pavlakis, Nick
Cooper, Caroline
John, Thomas
Kao, Steven
Klebe, Sonja
Lee, Chee Khoon
Leong, Trishe
Millward, Michael
O'Byrne, Ken
Russell, Prudence A.
Solomon, Benjamin
Cooper, Wendy A.
Fox, Stephen

December 2019

Lung cancer is the most commonly diagnosed malignancy and the leading cause of death from cancer glo...

Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.

Yoon Jin Cha
Jae Seok Lee
Hye Ryun Kim
Sun Min Lim
Byoung Chul Cho
Chang Young Lee
Hyo Sup Shim

ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...

Detection of ROS1 Gene Rearrangement in Lung Adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR

Ling Shan (155985)
Fang Lian (697007)
Lei Guo (36221)
Tian Qiu (156003)
Yun Ling (178318)
Jianming Ying (155982)
Dongmei Lin (495417)

March 2015

<div>AimsTo compare fluorescence in situ hybridization (FISH), immunohistochemistry...

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date

Gendarme, Sébastien
Bylicki, Olivier
Chouaid, Christos
Guisier, Florian

January 2022

The ROS-1 gene plays a major role in the oncogenesis of numerous tumors. ROS-1 rearrangement is foun...

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma : the ROSING Study

Conde, E.
Hernández, Susana
Martinez, R.
Angulo, B.
De Castro, J.
Collazo-Lorduy, A.
Jimenez, B.
Muriel, A.
Mate Sanz, Jose Luís
Morán, Teresa
Aranda, I.
Massuti, B.
Rojo, F.
Domine, M.
Sansano, Irene
Garcia, F.
Felip, Enriqueta
Mancheño, N.
Juan, O.
Sanz, Julián
Gonzalez-Larriba, J.L.
Atienza-Cuevas, L.
Arriola-Arellano, E.
Abdulkader, I.
Garcia-Gonzalez, J.
Camacho, C.
Rodriguez-Abreu, D.
Teixido, C.
Reguart, Noemi
Gonzalez-Piñeiro, A.
Lazaro-Quintela, M.
Lozano, M.D.
Gurpide, A.
Gomez-Roman, J.
Lopez-Brea, M.
Pijuan, Lara
Salido, Marta
Arriola, Edurne
Company, A.
Insa, A.
Esteban-Rodriguez, I.
Saiz, M.
Azkona, E.
Alvarez, R.
Artal, A.
Plaza, M.L.
Aguiar, D.
Enguita, A.B.
Benito, A.
Paz-Ares, L.
Garrido, P.
Lopez-Rios, F.
Universitat Autònoma de Barcelona

Altres ajuts: Funding for this study was provided bythe iLUNG Program (B2017/BMD-3884) from the Comu...

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort

Mazieres, Julien
Zalcman, Gerard
Crino, Lucio
Biondani, Pamela
Barlesi, Fabrice
Filleron, Thomas
Dingemans, Anne-Marie C.
Lena, Herve
Monnet, Isabelle
Rothschild, Sacha I.
Cappuzzo, Federico
Besse, Benjamin
Thiberville, Luc
Rouviere, Damien
Dziadziuszko, Rafal
Smit, Egbert F.
Wolf, Jurgen
Spirig, Christian
Pecuchet, Nicolas
Leenders, Frauke
Heuckmann, Johannes M.
Diebold, Joachim
Milia, Julie D.
Thomas, Roman K.
Gautschi, Oliver

March 2015

Purpose Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement. Crizoti...

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements

Yoon Jin Cha
Jae Seok Lee
Hye Ryun Kim
Sun Min Lim
Byoung Chul Cho
Chang Young Lee
Sup Shim

January 2014

ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...

Detection of ROSI rearrangement in non-small cell lung cancer: Current and future perspectives

Rossi G.
Jocolle G.
Conti A.
Tiseo M.
Marino F. Z.
Donati G.
Franco R.
Bono F.
Barbisan F.
Facchinetti F.

January 2017

ROS1 rearrangement characterizes a small subset (1%–2%) of non-small cell lung cancer and is associa...

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

Conde, E. (Esther)
Hernández, S. (Susana)
Martínez-Turrillas, R. (Rebeca)
Angulo, B. (Bárbara)
Castro, J. (Javier) de
Collazo-Lorduy, A. (Ana)
Jiménez, B. (Beatriz)
Muriel, A. (Alfonso)
Mate, J.L. (Jose Luis)
Moran, T. (Teresa)
Aranda, I. (Ignacio)
Massuti, B. (Bartomeu)
Rojo-Todo, F. (Federico)
Domine, M. (Manuel)
Sansano, I. (Irene)
García, F. (Felip)
Felip, E. (Enriqueta)
Mancheño, N. (Nuria)
Juan, O. (Oscar)
Sanz, J. (Julián)
Gonzalez-Larriba, J.L. (José Luis)
Atienza-Cuevas, L. (Lidia)
Arriola-Arellano, E. (Esperanza)
Abdulkader, I. (Ihab)
García-González, J (Jorge)
Camacho, C. (Carmen)
Rodríguez-Abreu, D. (Delvys)
Teixidó, C. (Cristina)
Reguart, N. (Noemi)
González-Piñeiro, A. (Ana)
Lázaro-Quintela, M. (Martín)
Lozano, M.D. (María Dolores)
Gurpide, A. (Alfonso)
Gomez-Roman, J. (Javier)
López-Brea, M. (Marta)
Pijuan, L. (Lara)
Salido, M. (Marta)
Arriola, E. (Edurne)
Company, A. (Amparo)
Insa, A. (Amelia)
Esteban-Rodríguez, I. (Isabel)
Saiz, M. (Mónica)
Azcona, E. (Eider)
Álvarez, R. (Ramiro)
Artal, Á. (Ángel)
Plaza, M.L. (María Luz)
Aguiar, D. (David)
Enguita, A.B. (Ana Belén)
Benito, A. (Amparo)
Paz-Ares, L. (Luis)
Garrido, P. (Pilar)
López-Ríos, F. (Fernando)

January 2019

Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of...

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort.

Mazières, Julien
Zalcman, Gérard
Crinò, Lucio
Biondani, Pamela
Barlesi, Fabrice
Filleron, Thomas
Dingemans, Anne-Marie C
Léna, Hervé
Monnet, Isabelle
Rothschild, Sacha I
Cappuzzo, Federico
Besse, Benjamin
Thiberville, Luc
Rouvière, Damien
Dziadziuszko, Rafal
Smit, Egbert F
Wolf, Jurgen
Spirig, Christian
Pecuchet, Nicolas
Leenders, Frauke
Heuckmann, Johannes M
Diebold, Joachim
Milia, Julie D
Thomas, Roman K
Gautschi, Oliver

March 2015

International audienceApproximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrang...

Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization

Abstract

Extracted data

Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization

Abstract

Extracted data

Related items

Related items